# Tevogen Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Tevogen Inc.).

## Overview

Tevogen Inc. is a U.S.-based biotechnology company developing immunotherapies for infectious diseases, cancer, and neurological disorders. Its pipeline includes TVGN 489, the ExacTcell technology platform, and Tevogen.AI, supported by research, preclinical, and clinical development capabilities.

## Products & services

• TVGN 489 T-cell therapy for COVID-19 and Long COVID
• ExacTcell precision immunotherapy technology
• Tevogen.AI drug discovery and development platform
• Preclinical immunotherapy programs for cancer
• Research programs for neurological disorders

- **TVGN 489** (55%) — Lead T-cell therapy candidate being developed for COVID-19 and Long COVID.
- **ExacTcell platform** (20%) — Technology platform intended to support targeted cellular immunotherapy development.
- **Tevogen.AI** (15%) — Artificial-intelligence initiative supporting drug discovery and product development.
- **Other pipeline programs** (10%) — Preclinical immunotherapy candidates addressing cancer and neurological disorders.

- TVGN 489 T-cell therapy for COVID-19 and Long COVID
- ExacTcell precision immunotherapy technology
- Tevogen.AI drug discovery and development platform
- Preclinical immunotherapy programs for cancer
- Research programs for neurological disorders

## Customers

Tevogen currently has no product customers because its candidates have not received marketing approval and the company has not generated product revenue. Potential customers include patients, healthcare providers, specialty pharmacies, payers, and government or institutional healthcare systems that could use or reimburse approved immunotherapies.

- **Patients with infectious diseases** (primary) — Potential recipients of TVGN 489 for COVID-19 and Long COVID if approved.
- **Cancer patients** (primary) — Potential users of future ExacTcell-enabled or other immunotherapy candidates.
- **Healthcare providers** (secondary) — Specialists and hospitals that could prescribe or administer approved therapies.
- **Payers and healthcare systems** (secondary) — Insurers and institutional buyers that could determine therapy access and reimbursement.
- **Research and development partners** (secondary) — CROs and investigative sites providing clinical and preclinical development services.

- Patients with COVID-19 or Long COVID could use approved TVGN 489
- Oncologists and specialists could administer cellular immunotherapies
- Payers could reimburse approved therapies for covered populations
- Hospitals and specialty pharmacies could support product distribution
- Research partners and CROs support clinical and preclinical development

## Geography

Tevogen's operations are based in the United States, with research and laboratory activities consolidated at a facility in Warren, New Jersey. The company previously operated a laboratory in Philadelphia, Pennsylvania, and its U.S. base supports clinical development, laboratory research, intellectual-property management, and future commercialization planning.

- United States is the company’s operating and development base
- Warren, New Jersey houses consolidated office and laboratory operations
- Philadelphia laboratory operations ended after the former lease expired
- U.S. location supports FDA-regulated clinical development
- Future commercialization would require broader distribution capabilities

## Strategy

Tevogen's strategy is centered on advancing TVGN 489 through clinical development while building additional immunotherapy candidates with ExacTcell and Tevogen.AI. The company is also developing research, manufacturing, and commercialization capabilities so it can support potential product launches if regulatory approvals are obtained. This asset-light, pipeline-driven model seeks to convert proprietary technology and clinical evidence into future therapy products.

- **Advance TVGN 489 clinical development** (short-term) — Clinical progress is the main pathway toward regulatory approval and future revenue.
- **Expand the immunotherapy pipeline** (medium-term) — Additional candidates can diversify the company beyond a single lead program.
- **Develop Tevogen.AI capabilities** (medium-term) — AI-supported discovery may improve candidate selection and development efficiency.
- **Establish manufacturing and commercialization infrastructure** (long-term) — Approved therapies require scalable production, market access, and distribution.

- Advance TVGN 489 through clinical development and regulatory milestones
- Use ExacTcell to expand targeted immunotherapy candidates
- Apply Tevogen.AI to accelerate discovery and development work
- Build manufacturing capabilities for potential future products
- Prepare commercialization, reimbursement, and distribution functions

## Risks

Tevogen is a pre-revenue biotechnology company exposed to clinical, regulatory, financing, manufacturing, and commercialization risks because its business depends on obtaining approval for future product candidates. The company states that substantial additional financing is required, while failure to meet Nasdaq listing requirements could impair access to public capital and reduce trading liquidity. Technology, intellectual-property, competitive, and healthcare-policy risks could also reduce the commercial value of its pipeline.

- **Clinical and regulatory failure** [critical] — TVGN 489 and future candidates require successful trials and regulatory authorization before commercialization.
- **Dependence on additional financing** [critical] — The company expects substantial funding needs for clinical development, AI initiatives, manufacturing, and commercialization.
- **Nasdaq listing compliance** [high] — Failure to meet minimum bid-price or market-value requirements could result in delisting and reduced financing access.
- **Manufacturing and supply execution** [high] — Cellular immunotherapies require specialized processes, facilities, quality controls, and reliable inputs.
- **Technology and intellectual-property risk** [high] — The value of ExacTcell, Tevogen.AI, and product candidates depends on protecting and validating proprietary technology.
- **Commercial adoption and reimbursement** [high] — Approved therapies may face payer restrictions, provider adoption barriers, competition, or unfavorable pricing.

- Clinical trials may fail to demonstrate safety or efficacy
- FDA approval may be delayed, restricted, or denied
- Additional financing may be unavailable or highly dilutive
- Manufacturing cellular therapies may prove costly or complex
- Nasdaq delisting could reduce liquidity and capital-market access
- Competitors may develop superior immunotherapy technologies

## Accounting

Tevogen prepares its consolidated financial statements under U.S. GAAP and has no product revenue, so reported results primarily reflect research and development, corporate, financing, and facility costs. Important estimates include accrued expenses, fair values of common stock and convertible promissory notes, and stock-based compensation. The Business Combination was accounted for as a reverse recapitalization, while the expanded Warren, New Jersey facility creates lease accounting and future fixed-cost considerations.

- **Revenue recognition** — Reported results remain focused on operating expenses and financing activity.
- **Research and development expense** — Trial timing and program activity can cause significant quarterly expense changes.
- **Fair value measurements** — Changes in valuation assumptions can affect liabilities, expenses, and reported equity.
- **Stock-based compensation** — Non-cash compensation increases operating expenses and affects reported loss.
- **Business combination accounting** — Historical financial statements and equity balances are presented as a continuation of Tevogen Bio.
- **Lease accounting** — Lease recognition affects assets, liabilities, depreciation, and interest expense.

- No product revenue is recognized before approval and commercialization
- R&D costs are expensed as clinical and preclinical work occurs
- Convertible note and equity values require fair-value estimates
- Stock-based compensation affects operating expense and equity
- Reverse recapitalization affects historical share presentation
- New Jersey facility lease creates right-of-use assets and liabilities

---

*Last updated: 2026-09-24T11:41:48.446152+00:00*